Fennec Pharmaceuticals Inc Sustainability Reports
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for cancer patients. Its lead product is PEDMARK (sodium thiosulfate injection), which is indicated to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 5299003IE70ITO2CBM73
FIGI: BBG001S69M23
5 reports from 2018 to 2025
